Souhaitez-vous accéder aux communiqués récents ?

Horizon Discovery Group plc ("Horizon" or "the Company") Preliminary Results for the Year Ended 31 December 2016 Revenue of £24.1m in line with guidance Revenue growth of 19% driven by...

KITCHENER, ON--(Marketwired - May 09, 2017) - The 14th annual MIT Sloan CIO Symposium today announced Vidyard was selected as a top 10 innovator for the 2017 Innovation Showcase. Vidyard's video...

BERKELEY, CA--(Marketwired - May 3, 2017) - Bonsai, provider of an emerging AI platform for programming intelligent systems, today announced that it has been selected as a finalist for the...

Data from Tazemetostat Phase 2 Programs in NHL and Molecularly Defined Solid Tumors Planned for Medical Meetings in Second Quarter Conference Call to Be Held Today at 8:30 a.m. Eastern Time ...

CAMBRIDGE, Mass., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the...

-- Transaction creates strong, diversified rare-disease focused portfolio-- Novelion Therapeutics completes concurrent financing of approximately $22 million -- Company to host conference call today...

CAMBRIDGE, Mass., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that President of...

CAMBRIDGE, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...

CAMBRIDGE, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the...

Robust Clinical Program Underway for Tazemetostat in Multiple Cancer Indications and Treatment Settings as Both Monotherapy and Combination Agent Conference Call to Be Held Today at 8:30 a.m....